Madrigal Pharmaceuticals Inc (MDGL) Stock Price, Quote & News

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 267 824 2827

Website: www.madrigalpharma.com

Address:

Four Tower Bridge, Suite 200 200 Barr Harbor Drive, West Conshohocken, United States

Biobroke Oct. 6 at 5:20 PM

$ALT if ALT had a similar reaction to $MDGL BTD we would be at ~$14

1 · Reply

Whiskeyunderthebed Oct. 6 at 2:37 PM

$MDGL curling up at $450 and waiting for earnings...

0 · Reply

ColdWatcher Oct. 5 at 11:31 AM

$MDGL Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.

0 · Reply

LiquidThetaLEAPS Oct. 5 at 9:14 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $443.01 Contracts: $MDGL December 18, 2026 $450 Calls Scale in: $84.15- $102.85 Scale out: $130.90-$168.30 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

GreenEnergy2022 Oct. 4 at 4:42 PM

$ALT The cT1 data we presented was extremely good! $MDGL $LLY $AKRO

1 · Reply

All_just_a_game Oct. 4 at 6:19 AM

$MDGL last year they report earnings end of October. Expect fabulous earnings.

0 · Reply

MoneyGroupLLC Oct. 4 at 1:52 AM

Enter: $MDGL NOV 21 2025 $470 CALLS Buy in Price: $32.00 - $37.00 Take Profit: $47.68 Stop Bleeding: $28.16 ROI Potential: 49% Exit Within: 313 Minutes https://moneygroup.us/alerts

0 · Reply

1986iamwallstreet Oct. 3 at 2:44 PM

$MDGL 500+ incoming 💸💸💸💸

0 · Reply

Hawksssss Oct. 3 at 2:14 PM

$MDGL they should split the shares. Will help liquidity

0 · Reply

Power2k Oct. 3 at 1:59 PM

$VKTX $MDGL Agree, BL should get someone to partner up with us on VK2809 even biopsies are demanded by FDA. We can't let MDGL to play monopoly in the MASH space. $GILD

0 · Reply

Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising

Sep 18, 2025, 4:05 PM EDT - 18 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 10:27 AM EDT - 4 weeks ago

Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 19, 2025, 4:05 PM EDT - 6 weeks ago

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Aug 15, 2025, 4:04 PM EDT - 7 weeks ago

Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further

Aug 11, 2025, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 8, 2025, 6:15 PM EDT - 2 months ago

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Aug 5, 2025, 5:44 PM EDT - 2 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Jul 31, 2025, 5:49 PM EDT - 2 months ago

Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term

Jul 30, 2025, 5:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Jul 25, 2025, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Jul 22, 2025, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Jul 16, 2025, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Jun 20, 2025, 7:35 AM EDT - 3 months ago

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Jun 20, 2025, 6:30 AM EDT - 3 months ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Jun 2, 2025, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

May 17, 2025, 8:10 AM EDT - 5 months ago

In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals

May 10, 2025, 7:15 AM EDT - 5 months ago

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

May 6, 2025, 4:20 PM EDT - 5 months ago

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra

May 1, 2025, 1:01 PM EDT - 5 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 5 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Apr 29, 2025, 8:00 AM EDT - 5 months ago

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Apr 18, 2025, 8:00 AM EDT - 6 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Apr 16, 2025, 7:00 AM EDT - 6 months ago

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Mar 11, 2025, 8:00 AM EDT - 7 months ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Feb 28, 2025, 2:29 PM EST - 7 months ago

Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)

Feb 26, 2025, 6:33 PM EST - 7 months ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 12:28 PM EST - 7 months ago

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Feb 26, 2025, 11:41 AM EST - 7 months ago

Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook

Feb 26, 2025, 11:05 AM EST - 7 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 7 months ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 6:30 AM EST - 7 months ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 21, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Jan 29, 2025, 11:50 AM EST - 8 months ago

MoneyShow's Best Investment Ideas For 2025: Part 7

ARCC ASML HESM IMMR MARA TOST VLGEA

Jan 19, 2025, 9:30 AM EST - 9 months ago

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

Jan 13, 2025, 6:45 AM EST - 9 months ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Jan 9, 2025, 6:22 AM EST - 9 months ago

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Jan 8, 2025, 11:13 AM EST - 9 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MRK PFE

Jan 3, 2025, 8:00 AM EST - 9 months ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 8:29 AM EST - 11 months ago

Top 3 Health Care Stocks That May Dip This Month

BFLY CNMD

Nov 6, 2024, 8:00 AM EST - 11 months ago

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Nov 3, 2024, 9:00 AM EST - 1 year ago

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Oct 31, 2024, 2:50 PM EDT - 1 year ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Oct 28, 2024, 3:42 AM EDT - 1 year ago

Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings

Oct 24, 2024, 12:11 PM EDT - 1 year ago

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Biobroke Oct. 6 at 5:20 PM

$ALT if ALT had a similar reaction to $MDGL BTD we would be at ~$14

1 · Reply

Whiskeyunderthebed Oct. 6 at 2:37 PM

$MDGL curling up at $450 and waiting for earnings...

0 · Reply

ColdWatcher Oct. 5 at 11:31 AM

$MDGL Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.

0 · Reply

LiquidThetaLEAPS Oct. 5 at 9:14 AM

0 · Reply

GreenEnergy2022 Oct. 4 at 4:42 PM

$ALT The cT1 data we presented was extremely good! $MDGL $LLY $AKRO

1 · Reply

All_just_a_game Oct. 4 at 6:19 AM

$MDGL last year they report earnings end of October. Expect fabulous earnings.

0 · Reply

MoneyGroupLLC Oct. 4 at 1:52 AM

Enter: $MDGL NOV 21 2025 $470 CALLS Buy in Price: $32.00 - $37.00 Take Profit: $47.68 Stop Bleeding: $28.16 ROI Potential: 49% Exit Within: 313 Minutes https://moneygroup.us/alerts

0 · Reply

1986iamwallstreet Oct. 3 at 2:44 PM

$MDGL 500+ incoming 💸💸💸💸

0 · Reply

Hawksssss Oct. 3 at 2:14 PM

$MDGL they should split the shares. Will help liquidity

0 · Reply

Power2k Oct. 3 at 1:59 PM

$VKTX $MDGL Agree, BL should get someone to partner up with us on VK2809 even biopsies are demanded by FDA. We can't let MDGL to play monopoly in the MASH space. $GILD

0 · Reply

Skipper6 Oct. 3 at 10:26 AM

$VKTX ...Just FYI Longs: Have you noticed $MDGL is now over 450/sh and at an ATH. I hope BL & team are still moving forward with VK2809?? I recall P2 data had best-in-class potential!! Congrats if any of you are still in MDGL!! Well done! Skipper

3 · Reply

1986iamwallstreet Oct. 3 at 2:38 AM

$MDGL been straight money this year , more To come

0 · Reply

SweepCastApp Oct. 2 at 9:02 PM

$MDGL: Unusual Options Activity Alerted CALL flow observed 5x contracts at Strike price of $390 Exp on 11/21/2025 with Premium of $37K and showing BEARISH Sentiment

0 · Reply

1986iamwallstreet Oct. 2 at 7:10 PM

$MDGL buyout is in play

1 · Reply

All_just_a_game Oct. 2 at 4:47 AM

$MDGL it’s possible this upcoming earnings release could be cash flow positive…but with the German launch costs might be close(r).

1 · Reply

WAJeff Oct. 1 at 5:39 PM

$MDGL $463.62 ath before the fade

0 · Reply

SweepCastApp Oct. 1 at 2:59 PM

$MDGL: Unusual Options Activity Alerted CALL flow observed 10x contracts at Strike price of $500 Exp on 12/19/2025 with Premium of $25K and showing NEUTRAL Sentiment

0 · Reply